7th annual Pre-Filled Syringes Conference and Exhibition

SMi are pleased to present Europe’s leading Pre-Filled Syringes Conference with 7 years of excellence at this well-established two day conference taking place on 28th- 29th January 2015.

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. This field is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. With the pharmaceutical industry expected to invest $10 billion of growth by 2018, the consensus is that sterile injectables remain an attractive prospect with room for significant growth to improve the quality of patients’ lives.

Pre-Filled Syringes are a fast and effective way to administer drugs and, as many pharmaceutical companies invest, the challenges faced for improvements still stand and must be addressed.

As innovation continues to flourish, this two day event will focus on administration, efficacy, compliance and accuracy in the design and development of pre-filled syringe manufacture, in addition to ensuring the most effective drug delivery system.

The issue of pre-filled syringe safety has received increased attention as of late, with both integrated pre-fillable safety syringes and safety solutions designed to accommodate existing pre-fillable syringes advancing commercially. A regulatory session in addition to risk assessment will be addressed at the conference.

In addition, automated manufacturing processes, injection processes, enhancements and advances in material for construction of pre-filled syringes are at the core of the PFS world and this conference will focus on addressing these key queries.
 

• This is a must attend event for those focusing on the latest developments and enhancements in the design and manufacturing of pre-filled syringes and injection devices.
• Insights from Key Opinion Leaders to benchmark against and gain understanding on current factors and market benefits of pre-filled syringes
• Delivery systems are evolving and quality is key in developing and enhancing delivery systems, take note from those accelerating in the design and development field of new PFS technologies
• Detailed regulatory considerations, new developments, industry challenges and risk assessment will be addressed to enhance product development, cost efficiency and efficacy

Abbvie Deutschland GmbH & Co. KG; Affibody; ALK Abello; APTAR PHARMA; Astech Projects; Barts Health Pharmaceuticals; Bath ASU; Bayer Pharma; BD Medical; BD Medical - Pharmaceutical Systems; bd medical pharmaceutical systems; Boehringer Ingelheim; Camurus A B; CP Partners Inc.; Datwyler Pharma Packaging; Fareva Corporate; Ferring International Center SA; ForthTox Limited; Fresenius Kabi Austria G M B H; Genentech; GlaxoSmithKline; GlaxoSmithKline plc; GSK; Hoffmann La Roche Ltd; Hospira Inc; Injector; IPI (International Pharmaceutical Industry); IPSEN; Johnson & Johnson; Laboratoire Aguettant; LUTO Research; Manchester Royal Infirmary; Medimmuno Inc; Merck & Co.; Merck Gmbh; MHRA; Nolato Medical; Novo Nordisk A/S; Optima Pharma; Owen Mumford; Owen Mumford Ltd; Panacol-Elosol GmbH; Pfizer; Pharma Publications; PLIVA; PsiOxus Therapeutics Ltd; Regeneron Pharma; Roche Holding; SCHOTT AG; Schreiner MediPharm; Somo; Southend University Hospital; Springboard; teamtechnik GmbH; UCB; VJ Electronix; West Pharmaceutical Services; Zeon Europe GmbH;

Venue